Vanden Bossche H, Marichal P, Le Jeune L, Coene M C, Gorrens J, Cools W
Division of Medicinal Chemistry and Pharmacology, Janssen Research Foundation, Beerse, Belgium.
Antimicrob Agents Chemother. 1993 Oct;37(10):2101-5. doi: 10.1128/AAC.37.10.2101.
As in other pathogenic fungi, the major sterol synthesized by Cryptococcus neoformans var. neoformans is ergosterol. This yeast also shares with most pathogenic fungi a susceptibility of its cytochrome P-450-dependent ergosterol synthesis to nanomolar concentrations of itraconazole. Fifty percent inhibition of ergosterol synthesis was reached after 16 h of growth in the presence of 6.0 +/- 4.7 nM itraconazole, and complete inhibition was reached at approximately 100 nM itraconazole. This inhibition coincided with the accumulation of mainly eburicol and the 3-ketosteroid obtusifolione. The radioactivity incorporated from [14C]acetate in both compounds represents 64.2% +/- 12.9% of the radioactivity incorporated into the sterols plus squalene extracted from cells incubated in the presence of 10 nM itraconazole. The accumulation of obtusifolione as well as eburicol indicates that itraconazole inhibits not only the 14 alpha-demethylase but also (directly or indirectly) the NADPH-dependent 3-ketosteroid reductase, i.e., the enzyme catalyzing the last step in the demethylation at C-4. This latter inhibition obviates the synthesis of 4,4-demethylated 14 alpha-methylsterols that may function at least partly as surrogates of ergosterol. Eburicol and obtusifolione are unable to support cell growth, and the 3-ketosteroid has been shown to disturb membranes. The complete inhibition of ergosterol synthesis and the accumulation of the 4,4,14-trimethylsterol and of the 3-ketosteroid together with the absence of sterols, such as 14 alpha-methylfecosterol and lanosterol, which can partly fulfill some functions of ergosterol, are at the origin of the high activity of itraconazole against C. neoformans. Fifty percent inhibition of growth achieved after 16 h of incubation in the presence of 3.2 +/- 2.6 nM itraconazole.
与其他致病真菌一样,新型隐球菌变种新型隐球菌合成的主要甾醇是麦角甾醇。这种酵母还与大多数致病真菌一样,其细胞色素P - 450依赖性麦角甾醇合成对纳摩尔浓度的伊曲康唑敏感。在6.0±4.7 nM伊曲康唑存在下生长16小时后,麦角甾醇合成受到50%的抑制,在约100 nM伊曲康唑时达到完全抑制。这种抑制与主要是表甾醇和3 - 酮甾醇钝叶红素的积累同时发生。在两种化合物中,从[14C]乙酸掺入的放射性占在10 nM伊曲康唑存在下孵育的细胞中提取的甾醇加角鲨烯中掺入放射性的64.2%±12.9%。钝叶红素以及表甾醇的积累表明伊曲康唑不仅抑制14α-脱甲基酶,还(直接或间接)抑制NADPH依赖性3 - 酮甾醇还原酶,即催化C - 4去甲基化最后一步的酶。后一种抑制避免了4,4 - 去甲基化的14α-甲基甾醇的合成,这些甾醇可能至少部分地作为麦角甾醇的替代物发挥作用。表甾醇和钝叶红素不能支持细胞生长,并且已表明3 - 酮甾醇会干扰细胞膜。麦角甾醇合成的完全抑制以及4,4,14 - 三甲基甾醇和3 - 酮甾醇的积累,再加上缺乏可部分履行麦角甾醇某些功能的甾醇,如14α-甲基粪甾醇和羊毛甾醇,是伊曲康唑对新型隐球菌具有高活性的原因。在3.2±2.6 nM伊曲康唑存在下孵育16小时后,生长受到50%的抑制。